Skip to content

PT-141 (Bremelanotide) Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

Very Common (greater than 10%):

  • Nausea (40% of patients in clinical trials vs 1% placebo), typically occurring within 30 minutes of injection and lasting approximately 2 hours; most pronounced with the first dose and diminishing with subsequent use
  • Flushing (20%)
  • Injection site reactions (13%)
  • Headache (11%)

Common (1 to 10%):

  • Vomiting (4.8%)
  • Cough (3.3%)
  • Fatigue (3.2%)
  • Hot flashes (2.7%)
  • Paresthesia (2.6%)
  • Dizziness (2.2%)
  • Nasal congestion (2.1%)
  • Upper respiratory tract infection
  • Transient skin hyperpigmentation at injection site

Cardiovascular Effects:

PT-141 causes transient increases in blood pressure, with peak elevations of approximately 6 mmHg systolic and 3 mmHg diastolic occurring 2 to 4 hours post-dose, accompanied by a reduction in heart rate of up to 5 beats per minute. Blood pressure and heart rate return to baseline within 12 hours. To minimize cardiovascular risk, patients should not exceed one dose per 24-hour period. This blood pressure elevation was the basis for the FDA's 2007 clinical hold on the intranasal formulation, and the cardiovascular warning remains on the approved Vyleesi label.

Contraindications:

  • Uncontrolled hypertension or known cardiovascular disease
  • Patients at high risk for cardiovascular events

Special Precautions:

The FDA prescribing information does not carry a boxed warning, but includes warnings and precautions regarding cardiovascular effects. Blood pressure should be well-controlled before initiating therapy, and periodic monitoring during treatment is recommended. PT-141 may reduce the rate and extent of absorption of concomitantly administered oral medications by slowing gastric motility, though clinical studies found this effect was not clinically relevant except for naltrexone, with which co-use should be avoided.

Anti-nausea medication such as ondansetron taken 30 minutes before PT-141 administration can significantly reduce the incidence and severity of nausea. Administering after a light meal may also help, though this has not been formally studied.

Frequently Asked Questions

Nausea is the most common side effect, affecting approximately 40% of patients and most pronounced with the first dose. Other common side effects include flushing (20%), injection site reactions (13%), and headache (11%). PT-141 also causes a transient rise in blood pressure and reduction in heart rate.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
  2. Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917.
  3. Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38.
  4. Safarinejad MR. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71.
  5. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
  6. Simon JA, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(1):61-68.
  7. U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557. 2019.
  8. Dhillon S. Bremelanotide: first approval. Drugs. 2019;79(14):1599-1606.
  9. Palatin Technologies. FDA approves new drug application for Vyleesi (bremelanotide injection). Press release. June 21, 2019.
  10. World Anti-Doping Agency. The 2026 Prohibited List. WADA.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”